NCT02286830View on ClinicalTrials.gov

Prolonged Protection From Bone Disease in Multiple Myeloma

PHASE4CompletedINTERVENTIONAL

Enrollment

158

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

February 16, 2023

Study Completion Date

February 16, 2023

Conditions

Multiple Myeloma

Interventions

DRUG

Zoledronic acid

Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.

Trial Locations (1)

5000

Odense University Hospital, Odense C

All Listed Sponsors

lead

Thomas Lund

OTHER

NCT02286830 - Prolonged Protection From Bone Disease in Multiple Myeloma | Biotech Hunter | Biotech Hunter